|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 Subunit
1 Reasearch Division, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
* To whom correspondence should be addressed. E-mail: laurie.goodyear{at}joslin.harvard.edu.
Naturally occurring mutations in the regulatory
subunit of 5[[rad]]-AMP activated protein kinase (AMPK) can result in pronounced pathological changes that may stem from increases in muscle glycogen levels, making it critical to understand the role(s) of the
subunit in AMPK function. In this study we cloned the mouse AMPK
3 subunit and revealed that there are two transcription start sites, which result in a long form,
3L (AF525500) and a short form,
3S (AF525501). AMPK
3L is the predominant form in mouse and is specifically expressed in mouse skeletal muscle at the protein level. In skeletal muscle, AMPK
3 shows higher levels of expression in fast-twitch white glycolytic muscle (type IIb) compared to fast-twitch red oxidative glycolytic muscle (type IIa), whereas
3 is undetectable in soleus muscle, a slow-twitch oxidative muscle with predominantly type I fibers. AMPK
3 can co-immunoprecipititate with both
and
AMPK subunits. Overexpression of
3S and
3L in mouse tibialis anterior muscle in vivo has no effect on
1 and
2 subunit expression and does not alter AMPK
2 catalytic activity. However,
3S and
3L overexpression significantly increases AMPK
1 phosphorylation and activity by approximately 50%. The increase in AMPK
1 activity is not associated with alterations in glycogen accumulation or glycogen synthase expression. In conclusion, the
3 subunit of AMPK is highly expressed in fast-twitch glycolytic skeletal muscle, and wild type
3 functions in the regulation of
1 catalytic activity, but it is not associated with changes in muscle glycogen concentrations.
This article has been cited by other articles:
![]() |
J. T. Treebak, J. B. Birk, B. F. Hansen, G. S. Olsen, and J. F. P. Wojtaszewski A-769662 activates AMPK {beta}1-containing complexes but induces glucose uptake through a PI3-kinase-dependent pathway in mouse skeletal muscle Am J Physiol Cell Physiol, October 1, 2009; 297(4): C1041 - C1052. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. R. Steinberg and B. E. Kemp AMPK in Health and Disease Physiol Rev, July 1, 2009; 89(3): 1025 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. W. Dolinsky and J. R. B. Dyck Role of AMP-activated protein kinase in healthy and diseased hearts Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2557 - H2569. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-J. Koh, D. E. Arnolds, N. Fujii, T. T. Tran, M. J. Rogers, N. Jessen, Y. Li, C. W. Liew, R. C. Ho, M. F. Hirshman, et al. Skeletal Muscle-Selective Knockout of LKB1 Increases Insulin Sensitivity, Improves Glucose Homeostasis, and Decreases TRB3 Mol. Cell. Biol., November 15, 2006; 26(22): 8217 - 8227. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yu, M. F. Hirshman, N. Fujii, J. M. Pomerleau, L. E. Peter, and L. J. Goodyear Muscle-specific overexpression of wild type and R225Q mutant AMP-activated protein kinase {gamma}3-subunit differentially regulates glycogen accumulation Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E557 - E565. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Jorgensen, E. A. Richter, and J. F. P. Wojtaszewski Role of AMPK in skeletal muscle metabolic regulation and adaptation in relation to exercise J. Physiol., July 1, 2006; 574(1): 17 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sriwijitkamol, J. L. Ivy, C. Christ-Roberts, R. A. DeFronzo, L. J. Mandarino, and N. Musi LKB1-AMPK signaling in muscle from obese insulin-resistant Zucker rats and effects of training Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E925 - E932. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Ryder, Y. C. Long, E. Nilsson, M. Mahlapuu, and J. R. Zierath Effects of calcineurin activation on insulin-, AICAR- and contraction-induced glucose transport in skeletal muscle J. Physiol., September 1, 2005; 567(2): 379 - 386. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. P Wojtaszewski, J. B Birk, C. Frosig, M. Holten, H. Pilegaard, and F. Dela 5'AMP activated protein kinase expression in human skeletal muscle: effects of strength training and type 2 diabetes J. Physiol., April 15, 2005; 564(2): 563 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pold, L. S. Jensen, N. Jessen, E. S. Buhl, O. Schmitz, A. Flyvbjerg, N. Fujii, L. J. Goodyear, C. F. Gotfredsen, C. L. Brand, et al. Long-Term AICAR Administration and Exercise Prevents Diabetes in ZDF Rats Diabetes, April 1, 2005; 54(4): 928 - 934. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |